Triple negative breast cancer
RecruitingEvaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression
Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression
- Disease:Triple negative breast cancer
- Substances:CarboplatinPaclitaxel+4
Germany- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Merck Sharp & Dohme LLC









